Trandolapril
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| ACE Inhibitors | Trandolapril | 0.5-2mg PO Q24H OR 2mg QHD (thrice weekly) | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 430 | 33 | 6-10 (active drug); 24 (trandolaprilat) | N/A | 80, 65-94 ([trandolaprilat] dependent) | 0.26 | N/A | Minimal (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00519
- Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007;27(5):522-9.